<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="tab2" orientation="portrait" position="float">
 <label>Table 2</label>
 <caption>
  <p>Duration of CHIK symptoms comparing patients with positive IgG using biological DMARDs with the controls and comparing anti-TNF biologicals with other bDMARDs.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <tbody>
   <tr>
    <td align="left" rowspan="1" colspan="1">Symptom duration</td>
    <td align="center" rowspan="1" colspan="1">bDMARD 
     <italic>N</italic> (%)
    </td>
    <td align="center" rowspan="1" colspan="1">Control 
     <italic>N</italic> (%)
    </td>
    <td align="center" rowspan="1" colspan="1">Total</td>
    <td align="center" rowspan="1" colspan="1">
     <italic>p</italic> value (ARR; 95% CI)
    </td>
   </tr>
   <tr>
    <td align="left" colspan="5" rowspan="1">
     <hr/>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">&lt;3 months</td>
    <td align="center" rowspan="1" colspan="1">23 (72%)</td>
    <td align="center" rowspan="1" colspan="1">5 (36%)</td>
    <td align="center" rowspan="1" colspan="1">28</td>
    <td rowspan="2" align="center" colspan="1">0.021 (−0.362; −0.457 to −0.266)</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">&gt;3 months</td>
    <td align="center" rowspan="1" colspan="1">9 (28%)</td>
    <td align="center" rowspan="1" colspan="1">9 (64%)</td>
    <td align="center" rowspan="1" colspan="1">18</td>
   </tr>
   <tr>
    <td align="left" colspan="5" rowspan="1">
     <hr/>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1"> </td>
    <td align="center" rowspan="1" colspan="1">
     <italic>Anti-TNF</italic>
    </td>
    <td align="center" rowspan="1" colspan="1">
     <italic>Control</italic>
    </td>
    <td align="left" rowspan="1" colspan="1"> </td>
    <td align="left" rowspan="1" colspan="1"> </td>
   </tr>
   <tr>
    <td align="left" colspan="5" rowspan="1">
     <hr/>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">&lt;3 months</td>
    <td align="center" rowspan="1" colspan="1">19 (95%)</td>
    <td align="center" rowspan="1" colspan="1">5 (36%)</td>
    <td align="center" rowspan="1" colspan="1">24</td>
    <td rowspan="2" align="center" colspan="1">0.001 (−0.593; −0.748 to −0.437)</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">&gt;3 months</td>
    <td align="center" rowspan="1" colspan="1">1 (5%)</td>
    <td align="center" rowspan="1" colspan="1">9 (64%)</td>
    <td align="center" rowspan="1" colspan="1">10</td>
   </tr>
   <tr>
    <td align="left" colspan="5" rowspan="1">
     <hr/>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1"> </td>
    <td align="center" rowspan="1" colspan="1">
     <italic>Other bDMARD</italic>
    </td>
    <td align="center" rowspan="1" colspan="1">
     <italic>Control</italic>
    </td>
    <td align="left" rowspan="1" colspan="1"> </td>
    <td align="left" rowspan="1" colspan="1"> </td>
   </tr>
   <tr>
    <td align="left" colspan="5" rowspan="1">
     <hr/>
    </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">&lt;3 months</td>
    <td align="center" rowspan="1" colspan="1">4 (33%)</td>
    <td align="center" rowspan="1" colspan="1">5 (36%)</td>
    <td align="center" rowspan="1" colspan="1">9</td>
    <td rowspan="2" align="center" colspan="1">0.899 (0.024; 0.040 to 0.008)</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">&gt;3 months</td>
    <td align="center" rowspan="1" colspan="1">8 (67%)</td>
    <td align="center" rowspan="1" colspan="1">9 (64%)</td>
    <td align="center" rowspan="1" colspan="1">17</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>bDMARD: biological disease-modifying antirheumatic drug; ARR: absolute risk reduction; other bDMARD included abatacept, rituximab, tocilizumab, and secukinumab.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
